{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:24:04Z","timestamp":1787243044034,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple system atrophy (MSA) is a severe neurodegenerative disorder with various underlying pathophysiological features. Mitochondrial dysfunction has been implied as a viable treatment target in patients with MSA. Yet, there is a lack of in-vivo studies examining regional metabolic differences between the Parkinsonian (MSAp) and the cerebellar (MSAc) subtype of MSA. Twenty-four patients with MSA (12 patients with MSAp and 12 patients with MSAc), 24 patients with Parkinson\u2019s disease (PD), and 24 age- and sex-matched healthy controls (HCs) underwent clinical evaluations and multimodal neuroimaging, including\n                    <jats:sup>31<\/jats:sup>\n                    P-MRSI targeting the basal ganglia and the cerebellum. Ratios of high-energy phosphorus-containing metabolites (HEPs) were compared between groups. Only patients with MSAc showed decreased HEP levels in the cerebellum. Conversely, no differences in basal ganglia HEP levels appeared between both MSA subtypes, patients with PD, or HCs. Our findings provide preliminary in-vivo evidence for regionally detectable bioenergetic alterations in the cerebellum of patients with MSAc, while basal ganglia results, particularly in MSAp, require cautious interpretation because of the spatial-resolution limits of the present\n                    <jats:sup>31<\/jats:sup>\n                    P-MRSI approach.\n                  <\/jats:p>","DOI":"10.1038\/s41531-026-01537-y","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:06:56Z","timestamp":1787238416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regional reduction of high-energy phosphorus metabolites characterizes the cerebellar subtype of multiple system atrophy"],"prefix":"10.1038","volume":"12","author":[{"given":"Jannik","family":"Prasuhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bodemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Reuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinja S.","family":"Gro\u00dfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Uter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Henkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Hanssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.nrl.2021.04.007","volume":"38","author":"M Carmona-Abellan","year":"2023","unstructured":"Carmona-Abellan, M. et al. Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases. Neurologia 38, 609\u2013616 (2023).","journal-title":"Neurologia"},{"key":"1537_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1210220","volume":"14","author":"M Goolla","year":"2023","unstructured":"Goolla, M., Cheshire, W. P., Ross, O. A. & Kondru, N. Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers. Front. Neurol. 14, 1210220 (2023).","journal-title":"Front. Neurol."},{"key":"1537_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-022-00283-4","volume":"11","author":"I Martinez-Valbuena","year":"2022","unstructured":"Martinez-Valbuena, I. et al. Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy. Transl. Neurodegener. 11, 7 (2022).","journal-title":"Transl. Neurodegener."},{"key":"1537_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06251-8","volume":"14","author":"O Lurette","year":"2023","unstructured":"Lurette, O. et al. Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization. Cell Death Dis. 14, 729 (2023).","journal-title":"Cell Death Dis."},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41593-022-01140-3","volume":"25","author":"ML Choi","year":"2022","unstructured":"Choi, M. L. et al. Pathological structural conversion of alpha- synuclein at the mitochondria induces neuronal toxicity. Nat. Neurosci. 25, 1134\u20131148 (2022).","journal-title":"Nat. Neurosci."},{"key":"1537_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.548283","volume":"8","author":"YM Jeon","year":"2020","unstructured":"Jeon, Y. M. et al. The role of glial mitochondria in alpha- synuclein toxicity. Front. Cell Dev. Biol. 8, 548283 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1537_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00401-019-01993-2","volume":"137","author":"D Hu","year":"2019","unstructured":"Hu, D. et al. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity. Acta Neuropathol. 137, 939\u2013960 (2019).","journal-title":"Acta Neuropathol."},{"key":"1537_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02484-0","volume":"19","author":"J Lu","year":"2022","unstructured":"Lu, J. et al. A breakdown in microglial metabolic reprogramming causes internalization dysfunction of alpha-synuclein in a mouse model of Parkinson\u2019s disease. J. Neuroinflamm. 19, 113 (2022).","journal-title":"J. Neuroinflamm."},{"key":"1537_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1326-9-44","volume":"9","author":"K Ogaki","year":"2014","unstructured":"Ogaki, K. et al. Analysis of COQ2 gene in multiple system atrophy. Mol. Neurodegener. 9, 44 (2014).","journal-title":"Mol. Neurodegener."},{"key":"1537_CR10","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1111\/ene.15475","volume":"29","author":"MC Kuo","year":"2022","unstructured":"Kuo, M. C. et al. COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition. Eur. J. Neurol. 29, 2956\u20132966 (2022).","journal-title":"Eur. J. Neurol."},{"key":"1537_CR11","doi-asserted-by":"crossref","unstructured":"Prasuhn, J., Kunert, L. & Br\u00fcggemann, N. Neuroimaging methods to map in vivo changes of OXPHOS and oxidative stress in neurodegenerative disorders. Int. J. Mol. Sci. 23, 7263 (2022).","DOI":"10.3390\/ijms23137263"},{"key":"1537_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mito.2019.09.010","volume":"50","author":"L Rani","year":"2020","unstructured":"Rani, L. & Mondal, A. C. Emerging concepts of mitochondrial dysfunction in Parkinson\u2019s disease progression: pathogenic and therapeutic implications. Mitochondrion 50, 25\u201334 (2020).","journal-title":"Mitochondrion"},{"key":"1537_CR13","doi-asserted-by":"crossref","unstructured":"Prasuhn, J., Davis, R.L. & Kumar, K.R. Targeting mitochondrial impairment in Parkinson\u2019s disease: challenges and opportunities. Front. Cell Dev. Biol. 8, 615461 (2020).","DOI":"10.3389\/fcell.2020.615461"},{"key":"1537_CR14","doi-asserted-by":"crossref","unstructured":"Khan, T. et al. Mitochondrial dysfunction: pathophysiology and mitochondria-targeted drug delivery approaches. Pharmaceutics 14, 2657 (2022).","DOI":"10.3390\/pharmaceutics14122657"},{"key":"1537_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101920","volume":"59","author":"J Mitsui","year":"2023","unstructured":"Mitsui, J. et al. High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo- controlled phase 2 trial. EClinicalMedicine 59, 101920 (2023).","journal-title":"EClinicalMedicine"},{"key":"1537_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12311-017-0846-9","volume":"16","author":"J Mitsui","year":"2017","unstructured":"Mitsui, J. et al. Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations. Cerebellum 16, 664\u2013672 (2017).","journal-title":"Cerebellum"},{"key":"1537_CR17","doi-asserted-by":"crossref","unstructured":"Jimenez-Jimenez, F. J., Alonso-Navarro, H., Garcia-Martin, E. & Agundez, J. A. G. Coenzyme Q10 and Parkinsonian syndromes: a systematic review. J. Pers. Med. 12, 975 (2022).","DOI":"10.3390\/jpm12060975"},{"key":"1537_CR18","doi-asserted-by":"publisher","first-page":"e2683","DOI":"10.1212\/WNL.0000000000201288","volume":"99","author":"J Prasuhn","year":"2022","unstructured":"Prasuhn, J. et al. Assessment of bioenergetic deficits in patients with Parkinson disease and progressive supranuclear palsy using (31)P-MRSI. Neurology 99, e2683\u2013e2692 (2022).","journal-title":"Neurology"},{"key":"1537_CR19","doi-asserted-by":"publisher","first-page":"e0147574","DOI":"10.1371\/journal.pone.0147574","volume":"11","author":"T Kasai","year":"2016","unstructured":"Kasai, T. et al. Serum levels of coenzyme Q10 in patients with multiple system atrophy. PLoS One 11, e0147574 (2016).","journal-title":"PLoS One"},{"key":"1537_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.parkreldis.2017.10.010","volume":"46","author":"Y Compta","year":"2018","unstructured":"Compta, Y. et al. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism Relat. Disord. 46, 16\u201323 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1537_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/jnen\/nlw037","volume":"75","author":"E Barca","year":"2016","unstructured":"Barca, E. et al. Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. J. Neuropathol. Exp. Neurol. 75, 663\u2013672 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1537_CR22","doi-asserted-by":"publisher","first-page":"e0149557","DOI":"10.1371\/journal.pone.0149557","volume":"11","author":"LV Schottlaender","year":"2016","unstructured":"Schottlaender, L. V. et al. Coenzyme Q10 levels are decreased in the cerebellum of multiple-system atrophy patients. PLoS One 11, e0149557 (2016).","journal-title":"PLoS One"},{"key":"1537_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fnins.2019.01187","volume":"13","author":"JT Hsiao","year":"2019","unstructured":"Hsiao, J. T., Purushothuman, S., Jensen, P. H., Halliday, G. M. & Kim, W. S. Reductions in COQ2 expression relate to reduced ATP levels in multiple system atrophy brain. Front. Neurosci. 13, 1187 (2019).","journal-title":"Front. Neurosci."},{"key":"1537_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2022.05.008","volume":"99","author":"J Prasuhn","year":"2022","unstructured":"Prasuhn, J. et al. The cerebellar bioenergetic state predicts treatment response in COQ8A-related ataxia. Parkinsonism Relat. Disord. 99, 91\u201395 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1537_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s10020-021-00426-9","volume":"28","author":"J Prasuhn","year":"2022","unstructured":"Prasuhn, J. et al. Relationship between brain iron deposition and mitochondrial dysfunction in idiopathic Parkinson\u2019s disease. Mol. Med. 28, 28 (2022).","journal-title":"Mol. Med."},{"key":"1537_CR26","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning, G. K. et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov. Disord. 37, 1131\u20131148 (2022).","journal-title":"Mov. Disord."},{"key":"1537_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1537_CR28","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/mds.20255","volume":"19","author":"GK Wenning","year":"2004","unstructured":"Wenning, G. K. et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord. 19, 1391\u20131402 (2004).","journal-title":"Mov. Disord."},{"key":"1537_CR29","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"1537_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.26712","volume":"94","author":"A Traschutz","year":"2023","unstructured":"Traschutz, A. et al. Responsiveness of the scale for the assessment and rating of ataxia and natural history in 884 recessive and early onset ataxia patients. Ann. Neurol. 94, 470\u2013485 (2023).","journal-title":"Ann. Neurol."},{"key":"1537_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/nbm.3384","volume":"28","author":"J Ren","year":"2015","unstructured":"Ren, J., Sherry, A. D. & Malloy, C. R. 31)P-MRS of healthy human brain: ATP synthesis, metabolite concentrations, pH, and T1 relaxation times. NMR Biomed. 28, 1455\u20131462 (2015).","journal-title":"NMR Biomed."},{"key":"1537_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117026","volume":"219","author":"P Coupe","year":"2020","unstructured":"Coupe, P. et al. AssemblyNet: a large ensemble of CNNs for 3D whole brain MRI segmentation. Neuroimage 219, 117026 (2020).","journal-title":"Neuroimage"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01537-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:45Z","timestamp":1787239965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01537-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01537-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"199"}}